CPT code 81339: MPL sequencing, exon 10 sequence analysis2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Sequence analysis of MPL exon 10 evaluates a gene associated with myeloproliferative neoplasms, including suspected essential thrombocythemia or myelofibrosis.
Medicare pays $185.20 for 81339 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$185.20
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2021
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 81339 covers
This molecular test sequences exon 10 of the MPL gene, which encodes the thrombopoietin receptor. Clinicians may order it when evaluating a suspected myeloproliferative neoplasm, particularly essential thrombocythemia or primary myelofibrosis. Molecular laboratories perform the analysis on patient DNA. Results can identify MPL variants relevant to the diagnostic evaluation.
Report 81339 for MPL exon 10 sequence analysis; the related 81338 code describes analysis of common MPL variants. Medicare pays this test through the CLFS only. The 2026 national CLFS amount is $185.20, unchanged from 2021 through 2026. One amount applies across states and localities, without geographic or office-versus-facility adjustment. The test is excluded from the physician fee schedule by statute.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 81339
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 81339. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 81339 with status X (excluded by statute), so the test itself is paid only from the CLFS.
81339 on the lab fee schedule since 2021
81339 · CLFS 2026 Q4 (current)
$185.20
Unchanged since Jan 1, 2021
24 quarterly CLFS releases on file, first CLFS 2021 Q1. A code missing from a quarter wasn’t on that release.
81339 compared with similar tests
- 81338MPL testingCommon variants$150.33
- Use 81339 for MPL exon 10 sequence analysis; 81338 is for analysis of common MPL variants.
- 81270JAK2 testV617F variant$91.66
- 81270 evaluates the JAK2 V617F variant, not MPL exon 10. The selected code follows the gene and analysis performed.
- 81219CALR testingCommon exon 9 variants$121.63
- 81219 evaluates common CALR variants, while 81339 analyzes MPL exon 10. These are different gene targets in myeloproliferative neoplasm testing.
81339 billing questions
How does 81339 differ from 81338?
81339 describes sequence analysis of MPL exon 10. Code 81338 describes analysis of common MPL variants, so select the code that matches the analysis performed.
What clinical workup commonly includes this test?
It may be ordered during evaluation of suspected essential thrombocythemia or primary myelofibrosis. MPL testing may be considered alongside testing for other myeloproliferative neoplasm markers, such as JAK2 or CALR.
Does Medicare pay 81339 under the physician fee schedule?
No. Medicare pays the test through the CLFS; it is excluded from the physician fee schedule by statute.
What should the documentation support?
Documentation should identify the clinical reason for molecular testing and show that the laboratory performed MPL exon 10 sequence analysis. The reported code should match the method and gene region tested.
Is payment adjusted for the laboratory's location or setting?
No. The CLFS amount is national and applies across localities, without a geographic or office-versus-facility adjustment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 81339 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist